Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors
摘要:
A cyclisation within a 4',5-bisthiazole (S)-proline-amide-urea series of selective PI3K alpha inhibitors led to a novel 4,5-dihydrobenzo[1,2-d: 3,4-d] bisthiazole tricyclic sub-series. The synthesis and optimisation of this 4,5-dihydrobenzo[1,2-d: 3,4-d] bisthiazole sub-series and the expansion to a related tricyclic 4,5-dihydrothiazolo[4,5-h] quinazoline sub-series are described. From this work analogues including 11, 12, 19 and 23 were identified as potent and selective PI3K alpha inhibitor in vivo tool compounds. (C) 2015 Elsevier Ltd. All rights reserved.
The present invention relates to compounds of formula I
and salts thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.